Physician profile
Keith M Lemire
NPI 1477511426
$2,565.50
in general payments reported to CMS, 2019-2025
25 companies · $334 in 2025
The $334 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $21.91 · 2021: $825 · 2022: $177 · 2023: $489 · 2024: $337 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $712.41 | 2021-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $310.18 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $188.48 | 2022-2025 | Tyrvaya |
| Alcon Vision LLC | $139.74 | 2019-2025 | Eysuvis, Tryptyr, Simbrinza |
| Ocular Therapeutix, INC. | $120.90 | 2024 | Dextenza |
| Hoffmann-La Roche Limited | $108.69 | 2019 | |
| Sun Pharmaceutical Industries INC. | $105.23 | 2019-2025 | |
| Apellis Pharmaceuticals, INC. | $104.77 | 2023 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $96.91 | 2019-2021 | |
| Abbvie INC. | $92.42 | 2022-2024 | |
| Allergan, INC. | $87.08 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $76.57 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $67.66 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $65.01 | 2022-2023 | |
| Shire North American Group INC | $58.35 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $31.50 | 2019 | |
| Merz Pharmaceuticals, LLC | $28.20 | 2023 | Xeomin |
| Harrow Eye, LLC | $26.93 | 2025 | Vevye |
| Dompe US, INC. | $26.03 | 2025 | Oxervate |
| Sight Sciences, INC. | $25.53 | 2023 | Tearcare System |
| Genzyme Corporation | $25.00 | 2021 | |
| Rayner Intraocular Lenses Limited | $21.14 | 2024 | Omidria |
| Horizon Therapeutics Plc | $15.96 | 2023 | Tepezza |
| Abb Con-Cise Optical Group LLC | $15.93 | 2023 | Contact Lens, Spectacle Lenses |
| Eyevance Pharmaceuticals LLC | $14.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Lemire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.